Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
What is Cancer?02:12

What is Cancer?

10.5K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
10.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer02:18

Cancer

47.7K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
47.7K
Cancer Vaccines01:30

Cancer Vaccines

333
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
333
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

8.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Colorectal cancer screening: An update to the American Cancer Society guideline, 2026.

CA: a cancer journal for clinicians·2026
Same author

Long-term trends in cancer mortality by rural-urban status, United States, 1969-2023.

Journal of the National Cancer Institute·2026
Same author

Colorectal cancer statistics, 2026.

CA: a cancer journal for clinicians·2026
Same author

Cancer statistics, 2026.

CA: a cancer journal for clinicians·2026
Same author

American Cancer Society's Report on the Status of Cancer Disparities in the United States, 2025.

CA: a cancer journal for clinicians·2025
Same author

Lobular breast cancer statistics, 2025.

Cancer·2025
Same journal

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

CA: a cancer journal for clinicians·2026
Same journal

Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.

CA: a cancer journal for clinicians·2026
Same journal

Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer.

CA: a cancer journal for clinicians·2026
Same journal

Nonpharmacologic interventions for managing distress, anxiety, and depression for patients with cancer and their family caregivers: A systematic review and meta-analysis.

CA: a cancer journal for clinicians·2026
Same journal

Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

CA: a cancer journal for clinicians·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

209

Cancer statistics, 2025.

Rebecca L Siegel1, Tyler B Kratzer1, Angela N Giaquinto1

  • 1Cancer Surveillance Research, American Cancer Society, Atlanta, Georgia, USA.

CA: a Cancer Journal for Clinicians
|January 16, 2025
PubMed
Summary
This summary is machine-generated.

Cancer mortality is declining due to prevention and treatment advances, but racial disparities and rising incidence in women threaten future progress. Addressing these inequalities is crucial for continued gains in cancer outcomes.

Keywords:
cancer casescancer statisticsdeath ratesincidencemortality

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:49

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

102

Related Experiment Videos

Last Updated: Jun 2, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

209
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:49

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

102

Area of Science:

  • Oncology
  • Public Health
  • Epidemiology

Background:

  • Cancer remains a significant public health concern in the United States, with annual estimates of new cases and deaths crucial for understanding disease burden.
  • While overall cancer mortality has declined, persistent and alarming racial disparities and shifts in incidence rates, particularly among women, necessitate urgent attention.

Purpose of the Study:

  • To present the latest statistics on cancer incidence and mortality in the United States for 2025, analyzing trends and disparities.
  • To highlight the impact of smoking reductions, early detection, and improved treatments on cancer mortality rates.
  • To identify and examine significant racial and gender-based disparities in cancer occurrence and outcomes.

Main Methods:

  • Utilized data from central cancer registries (through 2021) for incidence and the National Center for Health Statistics (through 2022) for mortality.
  • Analyzed population-based cancer occurrence and outcomes, focusing on trends in mortality rates, incidence ratios, and disparities across racial groups and genders.
  • Compared cancer incidence and mortality rates between men and women, and across different age groups and racial demographics.

Main Results:

  • Projected 2,041,910 new cancer cases and 618,120 cancer deaths in the U.S. for 2025.
  • Cancer mortality declined through 2022, averting an estimated 4.5 million deaths since 1991.
  • Significant racial disparities persist, with Native American and Black populations experiencing disproportionately higher mortality rates for several cancer types. Cancer incidence is rising in women, narrowing the male-to-female ratio, and surpassing male rates in certain age groups.

Conclusions:

  • Despite a continued decline in cancer mortality, progress is threatened by profound racial inequalities and an increasing burden of cancer in younger populations, especially women.
  • Addressing systemic inequities in cancer prevention and treatment access is imperative to overcome disparities and ensure equitable outcomes for all racial groups.
  • Future efforts must focus on targeted interventions for high-risk populations and continued investment in evidence-based cancer control strategies to maintain and accelerate mortality reductions.